Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Shagufta Mirza"'
Autor:
Farzana Haque, Jessamine Ryde, Laura Broughton, Chao Huang, Sifut Sethi, Andrew Stephens, Annet Pillai, Shagufta Mirza, Victoria Brown, Ged Avery, Georgios Bozas, Anthony Maraveyas
Publikováno v:
ERJ Open Research, Vol 9, Iss 3 (2023)
Background Clinical prediction rules (CPRs) developed to predict adverse outcomes of suspected pulmonary embolism (PE) and facilitate outpatient management have limitations in discriminating outcomes for ambulatory cancer patients with unsuspected PE
Externí odkaz:
https://doaj.org/article/e14c6402c0c4447891f6e6cc738cb028
Publikováno v:
Lung Cancer. 156:S38-S39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f17b02786c07c11b0e88f9088f6a7cf3
https://doi.org/10.1016/s0169-5002(21)00291-9
https://doi.org/10.1016/s0169-5002(21)00291-9
Autor:
Laura Feeney, Jenny Cotton, Shefali Parikh, Rebecca Lee, Shagufta Mirza, Anna Olsson-Brown, Ann Tivey, Abdulazeez Salawu, Mark Baxter, James Parry, Nadina Tinsley, Steven Zhao, Chris A. Jones, D.J. Hughes, Rohan Shotton, Lisa Jane Rodgers, Michael Rowe, Jonathan Heseltine, Alec Maynard, Caroline Dobeson
Publikováno v:
Journal of Clinical Oncology. 39:12026-12026
12026 Background: Immune checkpoint inhibitor (ICI) therapy is now commonly used in a range of tumours and settings. Most data relating to outcomes and rates of immune-related adverse events (irAE) is derived from clinical trial or registry populatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::632b6c54245d3d63b43b7d489fb91c66
https://doi.org/10.1200/jco.2021.39.15_suppl.12026
https://doi.org/10.1200/jco.2021.39.15_suppl.12026
Autor:
Shagufta Mirza, Nadina Tinsley, Laura Feeney, Alec Maynard, Caroline Dobeson, Anna Olsson-Brown, Sizheng Steven Zhao, Abdulazeez Salawu, Rebecca Lee, Mark Baxter, Chris A. Jones, Shefali Parikh, Sohail Mughal, Rohan Shotton, Lisa Jane Rodgers
Publikováno v:
Journal of Clinical Oncology. 38:7065-7065
7065 Background: Immune-related adverse events (irAE) are a recognised complication of immune checkpoint inhibitor (ICI) therapy. Previous characterisation of irAEs has been limited to clinical trial or registry populations and small case series. Her
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89d4da1c78bef5765860643c0f443253
https://doi.org/10.1200/jco.2020.38.15_suppl.7065
https://doi.org/10.1200/jco.2020.38.15_suppl.7065